United States Pharmaceuticals

Entasis Therapeutics Holdings Inc (ETTX)

Track

Track

Ticker: ETTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Entasis Therapeutics Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.4
Innoviva, Inc. Former 10% Owner Large shareholder
Transaction date
Purchase
Price
414.37
Quantity 24,190 +33.9%
Value US$1,293,753
2.4
Innoviva, Inc. Former 10% Owner Large shareholder
Transaction date
Purchase
Price
290.11
Quantity 54,165 -14.5%
Value US$3,346,825
Keiley Elizabeth M General Counsel Officer
Transaction date
Sale
Price
376.15
Quantity 83,975 +16.0%
Value US$2,539,373
Gutch Michael See Remarks Officer
Transaction date
Sale
Price
3.19
Quantity 3,759 -7.5%
Value US$11,991
Perros Manoussos See Remarks Executive Director
Transaction date
Sale
Price
3.19
Quantity 11,974 -7.5%
Value US$38,197
Mueller John Patrick Chief Development Officer Officer
Transaction date
Sale
Price
3.19
Quantity 4,001 -8.0%
Value US$12,763
Tommasi Ruben Chief Scientific Officer Officer
Transaction date
Sale
Price
3.19
Quantity 3,759 -5.2%
Value US$11,991
Ronsheim Matthew See Remarks Officer
Transaction date
Sale
Price
3.19
Quantity 3,759 -7.5%
Value US$11,991
Altarac David Chief Medical Officer Officer
Transaction date
Sale
Price
3.19
Quantity 3,759 -7.5%
Value US$11,991
2.4
Innoviva, Inc. Large shareholder
Transaction date
Purchase
Price
2.68
Quantity 4,672,897 +33.4%
Value US$12,499,999
2.4
Innoviva, Inc. Large shareholder
Transaction date
Purchase
Price
2.50
Quantity 12,677,490 +958.6%
Value US$31,693,725
Topper James N Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 375,887 +38.6%
Value US$5,638,305
Pivotal bioVenture Partners Fund I, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 337,724 +40.1%
Value US$5,065,860
Clarus Lifesciences III, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 453,395 +38.8%
Value US$6,800,925
Preston Heather Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 337,724 +40.1%
Value US$5,065,860
Sofinnova Venture Partners IX, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 337,724 +40.1%
Value US$5,065,860
TPG Group Holdings (SBS) Advisors, Inc.
Transaction date
Purchase
Price
15.00
Quantity 262,539 +34.6%
Value US$3,938,085
ASTRAZENECA PLC Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 246,666 +12.9%
Value US$3,699,990
Frazier Life Sciences VIII, L.P. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 375,887 +38.6%
Value US$5,638,305
GALAKATOS NICHOLAS Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 453,395 +38.8%
Value US$6,800,925
Novo Holdings A/S Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 1,089,835 +99.8%
Value US$16,347,525
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-07-13 2022-07-11 B Purchase
2.4
Innoviva, Inc.

Former 10% Owner

Large shareholder
24,190 +33.9%
414.37
US$1,293,753 		24,190 +33.9% 414.37 US$1,293,753
2022-07-13 2022-07-08 B Purchase
2.4
Innoviva, Inc.

Former 10% Owner

Large shareholder
54,165 -14.5%
290.11
US$3,346,825 		54,165 -14.5% 290.11 US$3,346,825
2021-10-20 2021-10-19 S Sale
Keiley Elizabeth M

General Counsel

Officer
83,975 +16.0%
376.15
US$2,539,373 		83,975 +16.0% 376.15 US$2,539,373
2021-10-20 2021-10-19 S Sale
Gutch Michael

See Remarks

Officer
3,759 -7.5%
3.19
US$11,991 		3,759 -7.5% 3.19 US$11,991
2021-10-20 2021-10-19 S Sale
Perros Manoussos

See Remarks

Executive Director
11,974 -7.5%
3.19
US$38,197 		11,974 -7.5% 3.19 US$38,197
2021-10-20 2021-10-19 S Sale
Mueller John Patrick

Chief Development Officer

Officer
4,001 -8.0%
3.19
US$12,763 		4,001 -8.0% 3.19 US$12,763
2021-10-20 2021-10-19 S Sale
Tommasi Ruben

Chief Scientific Officer

Officer
3,759 -5.2%
3.19
US$11,991 		3,759 -5.2% 3.19 US$11,991
2021-10-20 2021-10-19 S Sale
Ronsheim Matthew

See Remarks

Officer
3,759 -7.5%
3.19
US$11,991 		3,759 -7.5% 3.19 US$11,991
2021-10-20 2021-10-19 S Sale
Altarac David

Chief Medical Officer

Officer
3,759 -7.5%
3.19
US$11,991 		3,759 -7.5% 3.19 US$11,991
2020-09-01 2020-09-01 B Purchase
2.4
Innoviva, Inc.
Large shareholder
4,672,897 +33.4%
2.68
US$12,499,999 		4,672,897 +33.4% 2.68 US$12,499,999
2020-06-12 2020-06-11 B Purchase
2.4
Innoviva, Inc.
Large shareholder
12,677,490 +958.6%
2.50
US$31,693,725 		12,677,490 +958.6% 2.50 US$31,693,725
2020-01-13 2020-01-09 S Sale
3.9
Frazier Life Sciences VIII, L.P.
Large shareholder
50,000 -3.7%
5.00
US$250,010 		50,000 -3.7% 5.00 US$250,010
2018-10-02 2018-09-28 B Purchase Topper James N Non-Executive Director Large shareholder
375,887 +38.6%
15.00
US$5,638,305 		375,887 +38.6% 15.00 US$5,638,305
2018-10-02 2018-09-28 B Purchase Pivotal bioVenture Partners Fund I, L.P. Large shareholder
337,724 +40.1%
15.00
US$5,065,860 		337,724 +40.1% 15.00 US$5,065,860
2018-10-02 2018-09-28 B Purchase Clarus Lifesciences III, L.P. Large shareholder
453,395 +38.8%
15.00
US$6,800,925 		453,395 +38.8% 15.00 US$6,800,925
2018-10-02 2018-09-28 B Purchase Preston Heather Non-Executive Director Large shareholder
337,724 +40.1%
15.00
US$5,065,860 		337,724 +40.1% 15.00 US$5,065,860
2018-10-02 2018-09-28 B Purchase Sofinnova Venture Partners IX, L.P. Large shareholder
337,724 +40.1%
15.00
US$5,065,860 		337,724 +40.1% 15.00 US$5,065,860
2018-10-02 2018-09-28 B Purchase TPG Group Holdings (SBS) Advisors, Inc.
262,539 +34.6%
15.00
US$3,938,085 		262,539 +34.6% 15.00 US$3,938,085
2018-10-02 2018-09-28 B Purchase ASTRAZENECA PLC Large shareholder
246,666 +12.9%
15.00
US$3,699,990 		246,666 +12.9% 15.00 US$3,699,990
2018-10-02 2018-09-28 B Purchase Frazier Life Sciences VIII, L.P. Large shareholder
375,887 +38.6%
15.00
US$5,638,305 		375,887 +38.6% 15.00 US$5,638,305
2018-10-02 2018-09-28 B Purchase GALAKATOS NICHOLAS Non-Executive Director Large shareholder
453,395 +38.8%
15.00
US$6,800,925 		453,395 +38.8% 15.00 US$6,800,925
2018-10-01 2018-09-28 B Purchase Novo Holdings A/S Large shareholder
1,089,835 +99.8%
15.00
US$16,347,525 		1,089,835 +99.8% 15.00 US$16,347,525
Explore more

More insider trading research around Entasis Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America